Monthly Archives: April 2014

Gilead Sciences (GILD-NASDAQ, $70.59): A $17 Billion per annum Hepatitis C Market by 2017?

The model portfolio is adding shares of Gilead Sciences today. This represents the first NEW large cap purchase for the model portfolio in the second quarter of 2014. I have also purchased shares, today, as a personal investment. http://www.firstwordplus.com/therapy_trends_consensus_outlook_hepatitis_c.do

Posted in Portfolio Model Subscription